Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26650906 | 0.85 | USP30 (0.49) | USP30HDAC4RIPK2MEN1KMT2A | |
| SCHEMBL25105073 | 0.85 | ACKR3 (0.38) | HDAC4 | |
| SCHEMBL30158316 | 0.80 | THRB (0.45) | USP30LMNAALDH1A1THRBGPR119 | |
| SCHEMBL26650885 | 0.80 | THRB (0.45) | USP30LMNAALDH1A1THRBGPR119 | |
| SCHEMBL26650797 | 0.79 | BACE1 (0.41) | USP30MEN1KMT2ATHRBMAPT | |
| SCHEMBL30158421 | 0.79 | BACE1 (0.41) | USP30MEN1KMT2ATHRBMAPT | |
| SCHEMBL25151586 | 0.78 | USP30 (0.46) | USP30HDAC4RIPK2MEN1KMT2A | |
| SCHEMBL30158364 | 0.78 | JAK1 (0.42) | — | |
| SCHEMBL26650717 | 0.78 | JAK1 (0.42) | — | |
| SCHEMBL26650838 | 0.77 | LMNA (0.45) | USP30HDAC4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | USP30 3757/4885HDAC4 1172/4885RIPK2 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.